Market News & Trends
Senior Pharmaceutical Industry Executives Establish New Company & Business Model
Three highly experienced pharmaceutical and healthcare industry executives have formed next20, a new Thought Partnership, which provides strategic support to help healthcare and pharmaceutical companies…
Growth Hormone Therapy Market Favors Biobetters Over Biosimilars
The lack of biosimilars in the growth hormone deficiency (GHD) treatment pipeline does not signify a missed opportunity, because superior products exist in the form…
New Parsum IPP-80 In-Line Particle Sizing Probe: Robust, Trouble-Free Granulation Monitoring
The new Parsum IPP-80 probe from Malvern Instruments brings easy to integrate inline particle size measurement for efficient process monitoring and control. Suitable for powders,…
Needle-Free Technologies the Preferred Choice for Patients
BCC Research reveals in its new report on needle free technologies that during the past several decades, tremendous progress has been made toward the development…
With Stiff Competition From Biosimilars, Antibody Drugs Industry Revamping With Targeted Treatments
BCC Research reveals in its new report on antibody drugs that increasing competition and new technologies are propelling the market in a new direction. This…
Affinivax Announces Collaboration to Advance Lead Vaccine Candidate
Affinivax Inc. recently announced it has entered into a collaboration agreement with PATH, a global health nonprofit organization, to advance the company’s lead vaccine candidate…
SteadyMed Raises $12.2 Million
SteadyMed Ltd. recently announced it has secured $12.2 million in an equity financing. The financing was co-led by funds advised by subsidiaries of Federated Investors…
West Launches High-Quality Flip-Off Plus Seals
West Pharmaceutical Services, Inc. (NYSE: WST) recently announced the availability of a new sterile drug vial seal, the Flip-Off® PlusRU seal. Part of West’s Flip-Off®…
Noxilizer Announces Board of Directors Addition
Noxilizer, Inc. recently announced Herbert C. Buchanan Jr., President, IU Health Methodist and University Hospitals, will join its Board of Directors. The company plans to…
Vaxxas Raises $20 Million to Accelerate Commercialization of Novel Vaccine Platform
Vaxxas recently announced it has secured equity funding of $20 million from new and existing investors. These funds represent the first closing of a Series…
BioSpectra Welcomes New Director, Offering Direct Access to the Highest Compliance Excipients & APIs
BioSpectra recently announced the appointment of Thomas Donnelly as Director of Sales and Marketing. Mr. Donnelly will manage direct sales and business activities for BioSpectra…
Biological Therapies in Cancer Treatment to Reach $66 Billion in 2019
BCC Research reveals in its new report on biologic cancer treatment that access and affordability of cancer treatment options in various countries, along with a…
NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing's Sarcoma
LAGUNA HILLS, CA, February 9, 2015 – NanoSmart® Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from…
FDA Approves Genentech’s Lucentis (Ranibizumab Injection)
Genentech, a member of the Roche Group, recently announced that the US FDA approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR) in…
Achillion Achieves 100% SVR12 In Phase II Trial
Achillion Pharmaceuticals, Inc. recently announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase II study to evaluate the efficacy, safety, and tolerability of 6…
Strategic Science & Technologies Initiates Phase I Study to Evaluate Topical Sildenafil
Strategic Science & Technologies recently announced the initiation of a Phase I trial of SST-6006, a first-in-class topical sildenafil product candidate in development for the…
GlaxoSmithKline Encounters Initial Resistance Following Directional Shift
Following a less than flattering financial performance in 2014, GlaxoSmithKline plc (GSK) is realigning its operating structure with its corporate objectives and cashing in on…
La Jolla Pharmaceutical Company Announces Special Protocol Assessment For Planned Phase III Trial
La Jolla Pharmaceutical Company recently announced it has reached agreement with the US FDA on a Special Protocol Assesment (SPA) for its Phase III clinical…
Melinta Therapeutics Secures $30 Million From Hercules Technology Growth Capital
Melinta Therapeutics recently announced it has entered into a $30-million growth capital debt financing agreement with Hercules Technology Growth Capital, Inc. The initial funding of…
Consort Medical Signs Supply Agreement for Integrated Dose Counter
Consort Medical plc recently announced the conclusion of a significant new commercial supply agreement for its proprietary integrated dose counter (IDC) system. The multi-year supply…
